Shanghai Fudan-zhangjiang Bio-pharmaceutical Co., Ltd.

This study is testing a new drug called FDA018-ADC for people with advanced triple-negative breast cancer that has returned or worsened after standard taxane chemotherapy. It will compare the new drug to standard chemotherapy options chosen by the patient's doctor. The main goals…

This is a first-in-human, early-stage study to test the safety and find the right dose of a new experimental drug called FDA018-ADC in people with advanced solid tumors that have spread. The main goals are to see what side effects occur, how the drug moves through the body, and i…